Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects

• Published in: Journal of lipid research Vol. 59; no. 12; pp. 2397 - 2402
• Main Authors: Nandakumar, Renu, Matveyenko, Anastasiya, Thomas, Tiffany, Pavlyha, Marianna, Ngai, Colleen, Holleran, Stephen, Ramakrishnan, Rajasekhar, Ginsberg, Henry N., Karmally, Wahida, Marcovina, Santica M., Reyes-Soffer, Gissette
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2018; The American Society for Biochemistry and Molecular Biology; Elsevier
• Subjects: Adult; apoB antisense treatment; Apolipoprotein B-100 - blood; Cholesterol, LDL - blood; Chromatography, Liquid; Female; fractional clearance rate; Humans; Lipid Metabolism - drug effects; Lipoprotein(a) - blood; Male; Mass Spectrometry; Middle Aged; Oligodeoxyribonucleotides, Antisense - pharmacology; Oligonucleotides - pharmacology; Patient-Oriented and Epidemiological Research; production rate; fractional clearance rate; production rate; apoB antisense treatment

Elevated lipoprotein (a) [Lp(a)] levels increase the risk for CVD. Novel treatments that decrease LDL cholesterol (LDL-C) have also shown promise for reducing Lp(a) levels. Mipomersen, an antisense oligonucleotide that inhibits apoB synthesis, is approved for the treatment of homozygous familial hyp...